Pharmacogenomic Study to Predict Survival, Best Response and Toxicity in Newly Diagnosed Myeloma Patients Above the Age of 65 Treated With Either a Combination of Melphalan-Prednisone-Thalidomide or Lenalidomide-Dexamethasone.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dexamethasone; Lenalidomide; Melphalan; Prednisone; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
Most Recent Events
- 01 Apr 2021 Biomarkers information updated
- 01 Jun 2009 New trial record